



**The Canadian Association for Population Therapeutics presents:**

**“Effectiveness and Safety of Therapeutics:  
Dealing with Transparency, Minimizing Bias, and  
Improving Knowledge Translation to Concerned  
Stakeholders”**

## **PROGRAM**

**May 6<sup>th</sup> – 8<sup>th</sup>, 2012  
Montreal, Quebec  
Hyatt Regency Montreal**

## **CAPT MISSION & VISION**

The CAPT Mission is to advance population-based research of therapeutic interventions to improve the health outcomes of Canadians by:

- Bringing together diverse perspectives
- Facilitating open exchange of ideas and collaboration, and
- Influencing policy and practice

The CAPT Vision is to become the recognized Canadian leader for linking population-based therapeutic research, policy and practice to optimize health outcomes.

## **CAPT 2012 SCIENTIFIC PROGRAM COMMITTEE:**

Anick Bérard (Chair), University of Montreal

Farah Jivraj, sanofi-aventis Canada

Nicole Mittmann, HOPE Research Centre

Corine Mizrahi, CNODES

Wendy Morton, Merck Canada

Elham Rahme, McGill University

Angela Rocchi, Axia Research

## **CAPT 2012 LOCAL ORGANIZING COMMITTEE:**

Odile Sheehy (Chair), CHU Ste-Justine

Allan Gillman, IMS Brogan

**[www.capt-actp.com](http://www.capt-actp.com)**

# **“Effectiveness and safety of therapeutics: Dealing with transparency, minimizing bias, and improving knowledge translation to concerned stakeholders”**

## **Message from the President**

Welcome to the 2012 Canadian Association for Population Therapeutics (CAPT)/ Association Canadienne pour la Thérapeutique des Populations (ACTP) annual conference! We are pleased to be in Montreal this year to address drug safety and effectiveness from the perspectives of academia, industry and government, which makes CAPT distinct from other organisations.

Again this year, CAPT will be hosting extremely relevant symposiums, abstract sessions, a student event as well as a social event at the Musée d’Art Contemporain de Montréal. This year, an abstract session will be specifically dedicated to studies on safety and effectiveness. On behalf of the board of CAPT, we hope you enjoy the conference and look forward to the next few days of learning, discussing and networking with colleagues.

Anick Bérard  
CAPT President

## **CAPT 2012 Conference Overview**

Welcome to the 2012 CAPT/ACTP conference! The title of this year’s conference, ‘Effectiveness and safety of therapeutics: Dealing with transparency, minimizing bias, and improving knowledge translation to concerned stakeholders’, speaks to the need for good quality studies on drug safety and effectiveness in order to improve and increase knowledge translation and policy making. The Scientific Program Committee offers its sincere thanks to the sponsors who have made this conference possible.

The mission of CAPT/ACTP is to advance population-based research of therapeutic interventions to improve the health of Canadians by bringing together diverse perspectives, facilitating open exchange of ideas and collaboration, and influencing policy and practice. The Scientific Committee has designed the conference program to achieve this mission by inviting a wide variety of keynote speakers and panelists from all CAPT constituencies. This year for the first time, an advanced course on pharmacoeconomics will be offered. Finally, we have many exciting contributed presentations and posters. We encourage you to maximize your opportunities for interaction and exchange of ideas throughout the three days with both old and new colleagues and friends, and hope that you enjoy the conference.

Anick Bérard & Odile Sheehy  
2012 Scientific and Planning Committee

# **“Effectiveness and safety of therapeutics: Dealing with transparency, minimizing bias, and improving knowledge translation to concerned stakeholders”**

---

**Sunday, May 6, 2012**

---

**07:15 – 17:00          Registration (Soprano Foyer)**

## **Pre-Conference Symposium**

**Location: Soprano A&B**

Chair: Fabiano Santos, McGill University

**08:00 – 10:00          Introduction to Pharmacoepidemiology**  
Anaïs Lacasse, University of Quebec in Abitibi

**Demystifying Private Drug Plans**  
Suzanne Lepage, Suzanne Lepage Consulting

**10:00 – 10:30          Coffee Break ( Soprano Foyer)**

**10:30 – 12:00          Advanced Pharmacoeconomics : The QALY - Pros and Cons**  
Jean Lachaine, University of Montreal

**12:00 – 13:00          Welcome Lunch (Sponsored by: Novartis Pharmaceuticals)**  
(All conference registrants welcome)  
**Location: Soprano Foyer**

## **Conference Commencement**

**Location: Soprano A&B**

**13:00 – 13:15          Opening Remarks & Welcome**  
Anick Bérard, University of Montreal and President, CAPT

## **Issues Panel**

**Location: Soprano A&B**

**Sponsored by: Janssen**

---

**Sunday, May 6, 2012**

---

## **Biomarkers and Surrogate Outcomes: Linking Relevance, Regulation, and Reimbursement in Canada**

Chair: Mitchell Levine, McMaster University

- 13:15 – 13:30**      **Introductory Remarks**  
Mitchell Levine, McMaster University
- 13:30 – 13:55**      **Clinical Trials and Clinical Practice: Surrogates at the Clinician/Patient Interface**  
Linda Lévesque, Queen University
- 13:55 – 14:20**      **The Regulatory Perspective on Surrogates**  
Agnes Klein, Health Canada
- 14:20 – 14:45**      **The Impact of Surrogates in Reimbursement Recommendations**  
Angela Rocchi, Axia Research
- 14:45 – 15:15**      **Panel / Plenary Discussion**
- 15:15 – 15:45**      **Break & Contributed Poster Presentations**  
Location: Soprano C & Soprano Foyer

### **Contributed Oral Presentations**

#### **Concurrent Session 1: Pharmacoeconomic and Methodological Issues**

Location: Soprano A

Chair: Suzanne Cadarette, University of Toronto

- 15:45 – 16:00**      **Disease Risk Scores (DRS) as a Summary Confounder Method: Systematic Review and Recommendations**  
Mina Tadrous, University of Toronto
- 16:00 – 16:15**      **Economic Benefit of Subcutaneous Rapid Push Versus Intravenous Immunoglobulin Infusion Therapy in Adult Patients with Primary Immune deficiency**  
Mireille Goetghebeur, BioMedCom, Montreal

---

**Sunday, May 6, 2012**

---

- 16:15 – 16:30**      **The Impact of the Type of Drug Insurance Plan on Costs of Antidepressants and Statins**  
Lucie Blais, University of Montreal
- 16:30 – 16:45**      **Pharmacoeconomic Evaluation of 13-Valent Pneumococcal Conjugate and 23-Valent Pneumococcal Polysaccharide Vaccine in Canadian Adults**  
Andy W. Chuck, Institute of Health Economics
- 16:45 – 17:00**      **Relative Generic Usage and Drug Expenditures After Branded Patent Expiry: Not a Quick Enough Switch**  
Dahlia Balaban, University of Toronto
- 17:00 – 17:15**      **Treatment with Rivastigmine or Galantamine and Hospitalization for an Adverse Cardiac Event: a Dutch Database Study**  
Edeltraut Kroger, Centre d'excellence sur le vieillissement de Quebec

## **Concurrent Session 2: Validity of Exposure and Health Care Professional Involvement in Research**

**Location: Soprano B**

Chair: Robert Platt, McGill University

- 15:45 – 16:00**      **Impact of Exposure Misclassification Due to Incomplete Drug Data in Observational Studies of Safety and Effectiveness: a Cohort Study**  
Dean T. Eurich, University of Alberta
- 16:00 – 16:15**      **Pharmacy-Based Research Network: the Perception of Community Pharmacists**  
Lyle Lalonde, University of Montreal
- 16:15 – 16:30**      **A Review of Instruments Measuring Patient Attitudes Toward Antidiabetic Drug Therapy**  
Hervé Tchala Vignon Zomahoun, Laval University
- 16:30 – 16:45**      **The Effect of Treatment Adherence on Smoking Abstinence in Patients Post-Acute Myocardial Infarction**  
Sonia M. Grandi, McGill University
- 16:45 – 17:00**      **Development of a Questionnaire Measuring Psychosocial Determinants of Adherence to Oral Antidiabetic Drug Treatment**  
Gabriel Giguère, Laval University

---

## Sunday, May 6, 2012

---

- 17:00 – 17:15**      **Adherence to Antidiabetic Drug Treatment Among Workers with Type 2 diabetes**  
Mohamed Amine Amiche, Laval University
- 17:15 – 18:15**      **Reception (Sponsored by: Pfizer Canada) & Contributed Poster Presentations**  
**Location: Soprano C and Soprano Foyer**
- 18:00 – 20:00**      **Student Dinner (open to CAPT student registrants only)**  
**Location: Hyatt Regency Bar**

---

## Monday, May 7, 2012

---

- 07:00 – 17:00**      **Registration (Soprano Foyer)**
- 07:00 – 08:00**      **Breakfast (Sponsored by: Astellas Pharma Canada)**  
**Location: Soprano Foyer**

### **Keynote Speakers: Dealing with Bias, Maximizing Safety and Accessibility**

**Location: Soprano A&B**

Chair: Anick Bérard, University of Montreal

- 8:00 – 9:00**      **Time Related Bias in Pharmacoepidemiology?**  
Samy Suissa, McGill University
- 9:00 – 10:00**      **Drug Approval Process in Canada: Finding a Middle Ground Between Accessibility and Safety**  
Nigel Rawson, Eastlake Research Group
- 10:00 – 10:30**      **Break & Contributed Poster Presentations**

### **CNODES: Canadian Network for Observational Drug Effect Studies**

**Location: Soprano A&B**

**Sponsored by: CIHR / DSEN / CNODES**

Chair: Mitchell Levine, McMaster University

- 10:30 – 10:40**      **An Introduction to CNODES**  
Samy Suissa, McGill University

---

**Monday, May 7, 2012**

---

- 10:40 – 11:00**      **Statins and Acute Kidney Injury: A National Meta-Analyses of Observational Studies**  
Colin Dormuth, University of British Columbia
- 11:00 – 11:15**      **Strategies for Distributed Database Analysis**  
Michael Paterson, Institute for Clinical Evaluative Sciences
- 11:15 – 11:30**      **Proton-Pump Inhibitors and the Risk of Pneumonia: A Clinical Perspective**  
Laura E. Targownik, University of Manitoba
- 11:30 – 11:45**      **Proton-Pump Inhibitors and the Risk of Hospitalization for Community-Acquired Pneumonia: A National Meta-Analysis of Observational Studies**  
Kristian B. Fillion, McGill University
- 11:45 – 12:00**      **Antipsychotics and Hyperglycemic Emergencies: Study Design**  
Lorraine Lipscombe, University of Toronto
- 12:00 – 12:15**      **Methodological Challenges for Meta-Analyses of Observational Studies**  
Robert Platt, McGill University
- 12:15 – 12:30**      **Question & Answer Period**
- 12:30 – 13:30**      **Lunch (Sponsored by: Takeda Canada)**  
**Location: Soprano Foyer**
- 12:45-13:30**      **CAPT Annual General Meeting**  
**Location: Soprano A&B**

## **Engaging Patients and Citizens in HTA Decision Making**

**Location: Soprano A&B**

**Sponsored by: sanofi-aventis Canada**

Chair: Paul Oh, University Health Network



---

**Monday, May 7, 2012**

---

- 13:30 – 14:15**      **A Brokered Dialogue on the Experience of the Citizens Council in Ontario**  
Janet Parsons and Jim Lavery, Li Ka Shing Institute
- 14:15 – 14:35**      **Patients and Patient Associations in HTA both Nationally and Internationally**  
Durhane Wong - Reiger, President of CORD
- 14:35 – 15:00**      **Perspective as a Decision Maker on the Involvement of Patients and Citizens in HTA Decision Making**  
Gerald Evans, Past CED Chair of Ontario
- 15:00 – 15:30**      **Discussion and Question Period**
- 15:30 – 16:00**      **Break & Contributed Poster Presentations**  
Location: Soprano C & Soprano foyer

## **Contributed Oral Presentations**

### **Concurrent Session 1: Drug Safety and Effectiveness Studies**

Location: Soprano A

Sponsored by: CIHR / DSEN

Chair: Lucie Blais, University of Montreal

- 16:00 – 16:15**      **Survival with Adherence to Beta-Blocker Medications in Heart Failure: The 'Unhealthy- Adherer' Effect?**  
Wasem Alsabbagh, University of Saskatchewan
- 16:15 – 16:30**      **Cost-effectiveness of Intravenous Thrombolysis Compared to Best Medical Treatment for Late-Presentation Acute Ischemic Stroke in an Ontario Setting**  
Julian Nam, McMaster University
- 16:30 – 16:45**      **Variation in the Days Supply Field for Osteoporosis Medications in Ontario**  
Andrea M Burden, University of Toronto
- 16:45 – 17:00**      **Reliability of Exposure to Vaccine Products: Agreement Between Patients' Self-Report and Medical Records in the PGRx Database**  
Michel Rossignol, LA-SER

---

**Monday, May 7, 2012**

---

**17:00 – 17:15**      **The Efficacy and Safety of New Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis**  
Corey S Miller, McGill University

**17:15 – 17:30**      **Metformin Use and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes Mellitus**  
Brielan S Smiechowski, McGill University

## **Concurrent Session 2: Chronic Diseases**

**Location: Soprano B**

Chair: Elham Rahme, McGill University

**16:00 – 16:15**      **Description of Drug Utilization in Newly Diagnosed Patients with Pervasive Development Disorder in the Province of Quebec**  
Caroline Croteau, University of Montreal

**16:15 – 16:30**      **Trends in Post-Traumatic Use of Analgesics and Arthritic-Related Medications Following Lower-Limb Joint Injuries in the Population of the Province of Quebec, Canada**  
Julie Vaillancourt, McGill University

**16:30 – 16:45**      **Impact of Maternal Attachment on Children Development at 1-Year of Age: Results from the OTIS Antidepressants in Pregnancy Study**  
Fatiha Karam, University of Montreal

**16:45 – 17:00**      **Beware of Policy-Induced Selection Bias in Drug Effect Studies: Example in the Comparative Effectiveness of Oral Bisphosphonates**  
Suzanne M Cadarette, University of Toronto

**17:00 – 17:15**      **Are Deep Venous Thrombosis Events Accurately Identified Using Administrative Databases? A Systematic Review**  
Caroline Sirois, McGill University

**17:15 – 17:30**      **Systematic Follow-Up of Fragility Fractures: Preliminary Results of a Treatment Adherence**  
Sylvie Perreault, University of Montreal

---

## Monday, May 7, 2012

---

**18:00 – 20:00**      **Social Event – “Musée d’Art Contemporain de Montréal”**  
**Dinner Cocktail with 2 free drinks - Open to those with tickets**  
**Speakers:** Lucie Robitaille, Secretary General and Associate General Director of Organizational Development and Medications at INESSS and Diane Lamarre, President, Ordre des pharmaciens du Québec

---

## Tuesday, May 8, 2012

---

**07:30 – 13:00**      **Registration (Soprano Foyer)**

**07:00 – 08:00**      **Special Interest Group Breakfast: Medications and Pregnancy**  
**Location: Imagination**

**07:00 – 08:00**      **Breakfast (Sponsored by: GlaxoSmithKline Canada)**  
**Location: Soprano Foyer**

### **Canada’s Drug Effectiveness and Safety Network’ – How Are Other Jurisdictions Managing Real World Safety and Effectiveness and Are There Lessons for Canada?**

**Location: Soprano A&B**

**Sponsored by: Merck Canada**

Chair: William Dempster, 3Sixty Public Affairs

**8:00 – 8:20**      **DSEN’s Experience**  
Diane Forbes, DSEN

**8:20 – 8:40**      **Government Experience**  
Reiner Banken, INESSS

**8:40 – 9:00**      **Pharmaceutical Experience**  
William Dempster, 3Sixty Public Affairs Inc.

**9:00 – 9:20**      **US Experience**  
Sean Hennessy, University of Pennsylvania

**9:20 – 10:00**      **Panel / Plenary Discussion**

**10:00 – 10:30**      **Coffee Break**  
**Location: Soprano Foyer**

---

**Tuesday, May 8, 2012**

---

## **Lost Productivity and Indirect Costs**

**Location: Soprano A&B**

Chair: Nicole Mittmann, HOPE Research Centre

- 10:30 – 10:55**      **Use of Productivity Information by Private Plan Decision Makers when Assessing Value of New Medications and Treatments**  
Suzanne Lepage, Suzanne Lepage Consulting
- 10:55 – 11:20**      **Work Related Lost Productivity: What is the Economic Impact in Canadians Suffering with Psoriasis?**  
Brian Chan, University of Toronto
- 11:20 – 11:45**      **Financial Burden of Cancer on the Caregiver**  
Chris Longo, McMaster University
- 11:45 – 12:10**      **Patient Financial Burden from Wage Losses and Out-Of-Pocket Costs in the Year After Early Breast Cancer**  
Sophie Lauzier, Laval University
- 12:10 – 12:30**      **Panel Discussion & Questions**
- 12:30-13:00**      **Lunch (Sponsored by: Amgen Canada)**  
**Location: Soprano foyer**

## **Hot Topic Session – Sustainability of the Healthcare System, and Equitable and Timely Access to New Medications – Attainable Goals?**

**Location: Soprano A&B**

Chair: Jacques LeLorier, University of Montreal

- 13:00 – 13:25**      **Academic perspective:** Aslam Anis, University of British Columbia
- 13:25 – 13:50**      **Government perspective:** Lucie Robitaille, INESSS
- 13:50 – 14:15**      **Industry perspective:** Mark Fleming, Janssen
- 14:15 – 14:40**      **Patient perspective:** Harlon Davey, Committee to Evaluate Drugs
- 14:40 – 15:00**      **Discussion**
- 15:00-15:15**      **CAPT Awards Ceremony / Conference Close**  
Nicole Mittmann, Incoming CAPT President

---

## ORAL PRESENTATIONS

---

(Note: Presenting Authors are underlined)

1

Zomahoun HTV, Lauzier S, Guenette L, Moisan J **A review of instruments measuring patient attitudes toward antidiabetic drug therapy**

2

Amiche MA, Guenette L, Gregoire JP, Moisan J **Adherence to antidiabetic drug treatment among workers with type 2 diabetes**

3

Sirois C, Rahme E, Avina-Zubieta JA, Bertnatsky S, Lacaille D **Are deep venous thrombosis events accurately identified using administrative databases? A systematic review**

4

Cadarette SM, Levesque L, Mamdani MM, Perreault S, Juurlink DN, Paterson JM, Carney G, Gunraj N, Nikitovic M, Hawker GA, Dormuth CR **Beware of policy-induced selection bias in drug effect studies: example in the comparative effectiveness of oral bisphosphonates**

5

Nam J, O'Reilly D **Cost-effectiveness of intravenous thrombolysis compared to best medical treatment for late-presentation acute ischemic stroke in an Ontario setting**

6

Croteau C, Mottron L, Dorais M, Perreault S **Description of drug utilization in newly diagnosed patients with pervasive development disorder in the province of Quebec**

7

Giguere G, Guillaumie L, Lauzier S, Guenette L, Gregoire J-P, Moisan J **Development of a questionnaire measuring psychosocial determinants of adherence to oral antidiabetic drug treatment**

8

Tadrous M, Gagne JJ, Stürmer T, Cadarette SM **Disease Risk Scores (DRS) as a summary confounder method: systematic review and recommendations**

9

Martin A, Lavoie L, Goetghebeur M, Schellenberg R **Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency**

10

Gamble JM, Johnson JA, McAlister FA, Majumdar SR, Simpson SH, Eurich DT **Impact of exposure misclassification due to incomplete drug data in observational studies of safety and effectiveness: a cohort study**

11

Karam F, Sheehy O, Huneau MC, Briggs G, Chambers C, Einarson A, Johnson D, Kao K, Koren G, Martin B, Polifka JE, Riordan SH, Roth M, Voyer Lavigne S, Wolfe L, Bérard A and the OTIS Research Committee **Impact of maternal attachment on children development at 1-year of age: Results from the OTIS Antidepressants in Pregnancy Study**

12

Smiechowski BS, Suissa S, Azoulay L, Yin H, Pollak M **Metformin use and the incidence of colorectal cancer in patients with type 2 diabetes mellitus**

13

Chuck AW, Waye A, Zanotti G, Jacobs P, Tyrrell G, Kellner JD **Pharmacoeconomic evaluation of 13-Valent Pneumococcal Conjugate and 23-Valent Pneumococcal Polysaccharide Vaccine in Canadian Adults**

14

Hebert J, Laliberte MC, Berbiche D, Jouini G, Martin E, Lalonde L **Pharmacy-based research network: the perception of community pharmacists**

15

Balaban DY, Dhalla IA, Bell CM **Relative generic usage and drug expenditures after branded patent expiry: not a quick enough switch**

16

Bensouda-Grimaldi L, Rossignol M, Aubrun E, Leighton P, Bénichou J, Abenhaim L and the PGRx Group **Reliability of exposure to vaccine products: Agreement between patients' self-report and medical records in the PGRx database**

17

Alsabbagh MW, Lamb D, Blackburn DF **Survival with adherence to beta-blocker medications in heart failure: the 'Unhealthy-adherer' effect?**

18

Perreault S, Fernandes J, Delisle J, Beaubois C, Beaumont P, Benoit B, Gagnon S, Jodoin A, Laflamme Y, Leduc S, MacThiong JM, Malo M, Maurais G, Parent S, Ranger P, Troyanov Y **Systematic follow-up of fragility fractures : preliminary results of a treatment adherence**

19

Grandi SM, Filion KB, Gervais A, Joseph L, O'Loughlin J, Paradis G, Pilote L, Rinfret S, and Eisenberg MJ for the ZESCA Investigators **The effect of treatment adherence on smoking abstinence in patients post-acute myocardial infarction**

20

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ **The efficacy and safety of new oral anticoagulants versus warfarin in patients with atrial fibrillation: a systematic review and meta-analysis**

21

Blais L, Assayag J, Pare A, Forget A, Kettani FZ **The impact of the type of drug insurance plan on costs of antidepressants and statins**

22

Kroger E, Berkers M, Carmichael PH, Souverein P, van Marum R, Egberts T **Treatment with rivastigmine or galantamine and hospitalization for an adverse cardiac event: a dutch database study**

23

Vaillancourt J, Sampalis JSS **Trends in post-traumatic use of analgesics and arthritic-related medications following lower-limb joint injuries in the population of the province of Quebec, Canada**

24

Burden AM, Huang A, Tadrous M, Cadarette SM **Variation in the days supply field for osteoporosis medications in Ontario**

---

## POSTER PRESENTATIONS

---

25

Bartlett G, Longo C, Macgibbon B, Mayo N, Daskalopoulou S, Dawes M, Barnett T, Khayat Kholghi M **A novel knowledge translation approach for addressing the role of obesity in prescribing practices**

### 26 - ENCORE PRESENTATION

Bernatsky S, Lacaille D, O'Donnell S, Lix L, Bombardier C, and the Administrative Data Rheumatology Research and Surveillance Group **Administrative data in rheumatology research and surveillance: best practices**

27

Lalonde L<sup>1,2,3</sup>, Choiniere M<sup>4,5</sup>, Martin E<sup>2</sup>, Haworth C<sup>6</sup>, Bergeron D<sup>7</sup>, De GrandPre P<sup>8</sup>, Hudon E<sup>2,5</sup>, Gobeil F, Bourgault P, Tousignant-Laflamme E Y **AGIR: a self-management program for osteoarthritis patients and primary care clinicians supported by a group of Interdisciplinary regional clinicians**

## **28 - ENCORE PRESENTATION**

Diaby V, Lachaine J **An application of a proposed framework for formulary listing in low-income countries: the case of Cote d'Ivoire**

**29**

Muanda FT, Berard A **Antimalarial drugs and the risk for the pregnant women and fetuses: Review of the literature**

**30**

Morarescu E, Bouchard S, Beaulieu C **Antipsychotic use in elderly patients with dementia in Quebec, in 2006 and 2009**

**31**

Gamaoun R, Sheehy O, Berard A **Caffeine intake during pregnancy and the risk of preterm birth**

**32**

Morgan S, Cunningham C, Law M **Changing scientific and policy paradigms in the pharmaceutical sector: reflections from a program of research conducted in partnership with decision makers**

**33**

Savoie M **Comparative analysis of interprovincial and international legal framework and modalities for negotiations between public payers and pharmaceutical manufacturers on price and reimbursement of drug products - Proposal of a Conceptual Framework for Quebec**

**34**

Vicente C, Lynde C, Poulin Y, Sabapathy S, Boisjoly L, Piwko C **Cost-effectiveness of TOCTINO® (Alitretinoin) versus cyclosporine in adult patients with severe chronic hand eczema unresponsive to potent topical corticosteroids**

**35**

Beaulieu Boivin A, Choiniere M, Martin E, Berbiche D, Perreault S, Lussier D, Lalonde L **Costs of moderate to severe pain in primary care patients - A study of the Programme ACCORD**

**36**

Quintana-Barcena P, Lord A, Jouini G, Martin E, Beaunoyer S, Dumoulin-Charette A, Dupuis S, Guay M, Ricard S, Lalonde L **Development of a new tool to evaluate the severity of drug-related problems in chronic kidney disease patients**

**37**

Ma J, Ling N, Polk G **Disparities in access to cancer drugs as a result of provincial government pharmaceutical policies**



38

Chaabane S, Berard A **Epidemiology of major congenital malformations with specific focus on teratogens**

39

Besso A, Mazier P **Fat Consumption in First and Fourth Year University Students**

40

Paterson JM, Mamdani MM, Manno M, Juurlink DJ, and the Canadian Drug Safety and Effectiveness Research Network **Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study**

41 - ENCORE PRESENTATION

Ray W, Bernatsky S, Suissa S, Sylvestre MP, Abrahamowicz M **Glucocorticoid Therapy and Serious Infections in rheumatoid arthritis: a nested case-control study using a weighted cumulative dose model**

42

McCormick N, Marra CA, Colley L, Grubisic M, Sayre EC, Avina-Zubieta JA **Growing prescription drug costs, despite more efficient health care delivery, in cases with systemic autoimmune rheumatic diseases in British Columbia, Canada: a population-based study**

43

Gomes T, Camacho X, Hellings C, Juurlink D, Paterson JM, Laupacis A, Dhalla IA, Mamdani MM **High cost beneficiaries of the Ontario Drug Benefit (ODB) program**

44

Blais L, Kettani F-Z, Forget A **Impact of maternal asthma, its severity and control, on the risk of abortions**

45

Patil DS, Issa AM **Impact of Physician and Technology Factors on the Adoption of Personalized Genomic Diagnostics in Breast Cancer**

46

Zomahoun HTV, Guenette L, Moisan J **Interventions that improve adherence to oral antidiabetic in adults with type 2 diabetes: a systematic review**

47

Nam J, He J, O'Reilly D **Intra-arterial thrombolysis versus standard treatment or intravenous thrombolysis in adults with acute ischemic stroke: a systematic review and meta-analysis**

48

Forte L, Jobin M, Amin M, Boyle L, Richler D **Multi-criteria decision analysis: how does Canada measure up?**

49

Iskedjian M, McLean A, Berbari J, Farah B, Watson JA, Walker J, Gafni A, LeLorier J **No Starting Point Bias with the Bidding Game in a Willingness-to-Pay Analysis**

50

Laliberte MC, Perreault S, Damestoy N, Lalonde L **Perceptions of community pharmacists regarding their involvement in the management of osteoporosis and the risk of falls**

51

Vaillancourt J, Sampalis JSS **Post-traumatic use and cost of analgesics and arthritic-related medications following lower-limb joint injuries in the population of the province of Quebec, Canada**

52

Gamaoun R, Sheehy O, Berard A **Predictors of caffeine intake during pregnancy**

53

Mittmann N, Seung SJ, Hassan S, Bannon G, Craven BC **Preliminary results from the baseline questionnaire of the burden of bowel dysfunction in spinal cord injury study**

54

Beaulieu S, Bertin E, Bouvrette M, Daigneault AM, El Bouchikhi M, Forget R, Noel I, Bell R, Lord A, Jouini G, Martin E, Lalonde L **Programme ProFil - A training-and-communication network program in nephrology: an interim analysis**

55

Iskedjian M, Navarro V, Berbari J, LeLorier J **Systematic review of the literature on starting point bias in the bidding games of willingness-to-pay analyses**

56

Consiglio GP, Cadarette SM **Systematic review of the case-crossover design in pharmacoepidemiology**

57

Breton MC, Guenette L, Amiche MA, Kayibanda JF MA, Gregoire JP, Moisan J **The burden of type 2 diabetes on work productivity: a systematic review**

**58 - ENCORE PRESENTATION**

Filion KB, Grandi SM, Joseph L, O'Loughlin J, Paradis G, Pilote L, Rinfret S, Eisenberg MJ, and the ZESCA Investigators **The effect of bupropion on symptoms of depression among patients attempting to quit smoking post-myocardial infarction: The ZESCA Trial**

59

Eltonsy S, Kettani FZ, Blais L **The effect of SABA and LABA on fetal development and prematurity among asthmatic women: An updated**

60

Sheehy O, De Vera M, Kermarrec M, Blais L, Rahme E, Perreault S, Moisan J, Berard A **The impact of unmeasured confounders in cardiovascular studies performed in administrative databases**

61

Wu CQ, Grandi SM, Filion KB, Abenhaim HA, Joseph L, Eisenberg MJ **The Risk of Venous Thromboembolism of Drospirenone-Containing Combined Oral Contraceptives: A Systematic Review and Meta-Analysis**

62

Laliberte MC, Perreault S, Damestoy N, Lalonde L **The role of community pharmacists in health promotion and prevention: a cross-sectional study**

63

El-Hadi W, Dorais M, Raymond V **Thromboprophylaxis patterns in patients undergoing elective total knee and hip replacement surgery in the province of Quebec**

64

Lalonde L, Goudreau, J, Hudon E, Duhamel F, Lussier MT, Bareil C, Levesque L, Ladouceur M, Poirier N, Milard A **TRANSIT: a primary care interprofessional intervention program to improve the management of cardiovascular risk factors in patients with multiple chronic conditions**

65

Richard-Tremblay AA, Sheehy O, Berard A **Trends in dispensations of high dose folic acid and birth prevalence of major congenital malformations**

66

Gillman AF **Using Anonymized Longitudinal Patient Data to Monitor the Impact of Formulary Differences on Patient Treatment when Transitioning from Private to Public Coverage in Canada**

67

Blais L, Berard A, Kettani FZ, Forget A **Validation of congenital malformation diagnostic codes recorded in Quebec administrative databases**

68

Guenette L, Breton MC, Gregoire JP, Moisan J **Vascular protection with ACE inhibitors or angiotensin II receptor antagonists following type 2 diabetes treatment initiation in elderly**

69

Rawson NSB **When the Risk of Confounding by Indication is High, Are Administrative Data Adequate to Achieve Scientific Excellence in Pharmacoepidemiology?**



## 2012 CAPT / ACTP CONFERENCE SPONSORS

### PLATINIUM

DSEN / CHIR (logo)  
Janssen (logo)  
Merck Canada (logo)  
sanofi-aventis Canada (logo)

### GOLD

Amgen Canada (logo)  
Astellas Pharma Canada (logo)  
CNODES / CIHR (logo)  
GlaxoSmithKline (logo)  
Novartis Pharmaceuticals (logo)  
Pfizer Canada (logo)  
Takeda Canada (logo)

### SILVER

Axia Research (logo)  
Bayer Canada (logo)  
Canada's Research-Based Pharmaceutical Companies (Rx&D) (logo)  
LA-SER (logo)  
OptumInsight Life Sciences (logo)  
Purdue Pharma (logo)  
StatSciences (logo)  
Union Chimique Belge (UCB) (logo)

### BRONZE

Cornerstone Research (logo)  
HOPE Research Centre (logo)  
Institute of Health Economics (logo)  
Oxford Outcomes (logo)  
Servier Canada (logo)